Please login to the form below

Not currently logged in
Email:
Password:

haemophilia A

This page shows the latest haemophilia A news and features for those working in and with pharma, biotech and healthcare.

Roche gets wider approval for haemophilia drug Hemlibra

Roche gets wider approval for haemophilia drug Hemlibra

Roche says that Hemlibra is the first drug to show an improvement over standard haemophilia A treatment, cutting bleeds by two-thirds (68%) compared to earlier factor VIII prophylaxis. ... a saving over the current costs of treating haemophilia A,

Latest news

  • Bayer roll-out of haemophilia drug Jivi gathers pace Bayer roll-out of haemophilia drug Jivi gathers pace

    Bayer has added another big market for its new haemophilia A product Jivi, adding approval in Japan to a green light in the US a few weeks ago. ... Jivi is another option in an increasingly crowded market for haemophilia A therapies, and Bayer is hoping

  • Sanofi gets EU OK for Ablynx flagship drug Cablivi Sanofi gets EU OK for Ablynx flagship drug Cablivi

    At the moment, people with aTTP have to be treated with daily plasma exchange (PEX) and immunosuppressive drugs, and are still a high risk of serious breakthrough attacks that can be ... of Bioverativ earlier this year which added two marketed

  • Roche highlights Hemlibra data as key FDA date approaches Roche highlights Hemlibra data as key FDA date approaches

    time that any drug has shown an improvement over the current standard haemophilia A therapy. ... ICER) described as “cost-saving”given that the current costs of treating haemophilia A are huge.

  • Spark sputters on haemophilia A gene therapy safety scare Spark sputters on haemophilia A gene therapy safety scare

    Spark sputters on haemophilia A gene therapy safety scare. Investors compare data unfavourably with BioMarin rival. ... Gene therapy developer Spark Therapeutics has seen around $1bn carved off its value after it emerged that two patients in its

  • Immunology keeps Shire figures solid as Takeda takeover nears Immunology keeps Shire figures solid as Takeda takeover nears

    $612m but the company’s haematology franchise – including haemophilia products acquired along with Baxalta in 2016 – down 1% to $951m. ... There were gains for long-acting haemophilia A drug Adynovate, which has been on the market since 2015 but

More from news
Approximately 16 fully matching, plus 87 partially matching documents found.

Latest Intelligence

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    lives, with the effect lasting a median of 33 months after just one treatment. ... Gilead and Novartis aside, the only companies with a stake in gene therapy with a higher market capitalisation are BioMarin, in pole position to develop a potentially

  • ‘How is your day?’ ‘How is your day?’

    World champion cyclist Alex Dowsett lives with severe haemophilia. He also speaks for ‘How Is Your Day? ’. ... plasma. Haemophilia is a condition that can be treated by both laboratory-produced recombinant plasma therapies or medicines made from

  • Deal Watch January 2018

    Paying $105 per share in cash (64% premium over Bioverativ’s closing price on 19 January), Sanofi gains the marketed products, Eloctate (haemophilia A therapy) and Alprolix (haemophilia B therapy), as ... Strategically caplacizumab represented a good

  • The good, the bad and the ugly The good, the bad and the ugly

    However, investors fear that challenges in the $11bn haemophilia market could lead to a slump in the haemophilia business it inherited through the Baxalta purchase. ... These two players will have a comfortable advantage over their nearest rival - Roche (

  • Attracting doctors to low-demand specialties Attracting doctors to low-demand specialties

    Haemophilia. One of the specialties in which Porterhouse has worked for many years is haemophilia, a disease that finds itself in a somewhat anomalous position. ... such as leukaemias, lymphomas and myelomas, while haemophilia warrants just one or two

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

  • Anne Prener to lead Freeline Therapeutics Anne Prener to lead Freeline Therapeutics

    Freeline comprises some of the world’s leading experts in gene therapy, haemophilia and other debilitating disorders and I look forward to working closely with them to demonstrate the potential of ... She has also worked at Novo Nordisk as senir vice

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Living with haemophilia – the power of knowledge

    Haemophilia is a genetic disorder that prevents blood from clotting [1]. It is a predominantly male disorder, with haemophilia A occurring in 1 in 5, 000 live male births [1]. ... Untreated, haemophilia can be extremely debilitating, making everyday

  • Attracting doctors to low-demand specialties: A role for industry?

    Haemophilia. One of the specialties in which Porterhouse has worked for many years is haemophilia, a disease that finds itself in a somewhat anomalous position. ... such as leukaemias, lymphomas and myelomas, while haemophilia warrants just one or two

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics